Bolt Biotherapeutics, Inc.
BOLT
$3.68
-$0.18-4.71%
NASDAQ
| 06/30/2026 | 03/31/2026 | 12/31/2025 | 09/30/2025 | 06/30/2025 | |
|---|---|---|---|---|---|
| Revenue | 5.00K | 26.00K | 2.50M | 2.17M | 1.80M |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | 5.00K | 26.00K | 2.50M | 2.17M | 1.80M |
| Cost of Revenue | 5.15M | 4.59M | 4.99M | 6.54M | 7.50M |
| Gross Profit | -5.14M | -4.56M | -2.49M | -4.37M | -5.69M |
| SG&A Expenses | 2.42M | 2.80M | 3.12M | 3.34M | 3.52M |
| Depreciation & Amortization | -- | -- | -- | -- | -- |
| Other Operating Expenses | -- | -- | -- | -- | -- |
| Total Operating Expenses | 7.57M | 7.63M | 8.11M | 9.87M | 11.01M |
| Operating Income | -7.57M | -7.60M | -5.61M | -7.70M | -9.21M |
| Income Before Tax | -7.72M | -7.24M | -6.63M | -7.14M | -8.56M |
| Income Tax Expenses | -- | -- | -- | -- | -- |
| Earnings from Continuing Operations | -7.72M | -7.24M | -6.63M | -7.14M | -8.56M |
| Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -- | -- | -- | -- | -- |
| Net Income | -7.72M | -7.24M | -6.63M | -7.14M | -8.56M |
| EBIT | -7.57M | -7.60M | -5.61M | -7.70M | -9.21M |
| EBITDA | -7.40M | -7.40M | -5.35M | -7.41M | -8.86M |
| EPS Basic | -4.57 | -4.31 | -3.84 | -3.72 | -4.46 |
| Normalized Basic EPS | -2.56 | -2.69 | -1.86 | -2.33 | -2.79 |
| EPS Diluted | -4.57 | -4.31 | -3.84 | -3.72 | -4.46 |
| Normalized Diluted EPS | -2.56 | -2.69 | -1.86 | -2.33 | -2.79 |
| Average Basic Shares Outstanding | 1.69M | 1.68M | 1.73M | 1.92M | 1.92M |
| Average Diluted Shares Outstanding | 1.69M | 1.68M | 1.73M | 1.92M | 1.92M |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |